Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10540020 | 1.00 | MEN1 (0.50) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL11579370 | 0.95 | DGKA (0.54) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL2922616 | 0.95 | DGKA (0.54) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL207583 | 0.95 | DGKA (0.54) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL6417620 | 0.95 | DGKA (0.54) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL822405 | 0.93 | MEN1 (0.48) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL1532510 | 0.93 | DGKA (0.57) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL28736945 | 0.93 | DGKA (0.57) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL28474000 | 0.93 | DGKA (0.57) | MEN1KMT2AEPHX2DGKATSHR | |
| SCHEMBL1863163 | 0.93 | DGKA (0.52) | MEN1KMT2AEPHX2DGKATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130612-A1 | COMPOSITION CONTAINING CHITOSAN FOR SUSTAINED DRUG RELEASE | THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO. (JO) | 2010-05-27 | — | — | US | disclosed |
| CN-101267839-A | Chitosan-silicon dioxide coprecipitate and use as excipient in solid dosage forms | JORDANIAN PHARMACEUTICAL MFG (JO) | 2008-09-17 | — | — | CN | disclosed |
| US-20080214677-A1 | Chitosan-Silicon Dioxide Coprecipitate and Use as Excipient in Solid Dosage Forms | THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO. (JO) | 2008-09-04 | — | — | US | disclosed |
| EP-1759711-B1 | Chitosan-silicon dioxide coprecipitate and use as excipient in solid dosage forms | JORDANIAN PHARMACEUTICAL MFG (JO) | 2008-06-11 | — | — | EP | disclosed |
| EP-1693051-B1 | Composition containing chitosan for sustained drug release | JORDANIAN PHARMACEUTICAL MFG (JO) | 2008-06-04 | — | — | EP | disclosed |
| EP-1512394-B1 | Universal controlled-release composition comprising chitosan | JPM THE JORDANIAN PHARMACEUTIC (JO) | 2008-03-26 | — | — | EP | disclosed |
| EP-1852110-A1 | Co-precipitate of chitin or chitin derivative and a silicon dioxide or derivative for the use as tablet excipient | The Jordanian Pharmaceutical Manufacturing Co. Ltd. (JO) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007121848-A1 | CO-PRECIPITATE OF CHITIN OR CHITIN DERIVATIVE AND A SILICON DIOXIDE OR DERIVATIVE FOR THE USE AS TABLET EXCIPIENT | THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO. (JO) | 2007-11-01 | — | — | WO | disclosed |
| EP-1848397-A1 | COMPOSITION CONTAINING CHITOSAN FOR SUSTAINED DRUG RELEASE | The Jordanian Pharmaceutical Manufacturing Co. (JO) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007025715-A1 | CHITOSAN-SILICON DIOXIDE COPRECIPITATE AND USE AS EXCIPIENT IN SOLID DOSAGE FORMS | THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO. (JO) | 2007-03-08 | — | — | WO | disclosed |
| EP-1759711-A1 | Chitosan-silicon dioxide coprecipitate and use as excipient in solid dosage forms | The Jordanian Pharmaceutical Manufacturing Co. (JO) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006087028-A1 | COMPOSITION CONTAINING CHITOSAN FOR SUSTAINED DRUG RELEASE | THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO. (JO) | 2006-08-24 | — | — | WO | disclosed |
| EP-1693051-A1 | Composition containing chitosan for sustained drug release | The Jordanian Pharmaceutical Manufacturing Co. (JO) | 2006-08-23 | — | — | EP | disclosed |
| EP-1299089-B1 | DRUG DELIVERY SYSTEM FOR POORLY WATER SOLUBLE DRUGS | KEMESTRIE INC (CA) | 2006-04-12 | — | — | EP | disclosed |
| US-20050281873-A1 | Universal controlled-release composition | THE JORDANIAN PHARMACEUTICAL MANUFACTURING CO. (JO) | 2005-12-22 | — | — | US | disclosed |
| EP-1512394-A1 | Universal controlled-release composition comprising chitosan | JPM - The Jordanian Pharmaceutical Manufacturing Co. Ltd. (JO) | 2005-03-09 | — | — | EP | disclosed |
| US-20030157171-A1 | Drug delivery system for poorly water soluble drugs | KEMESTRIE INC. (CA) | 2003-08-21 | — | — | US | disclosed |
| EP-1299089-A2 | DRUG DELIVERY SYSTEM FOR POORLY WATER SOLUBLE DRUGS | Kemestrie Inc. (CA) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002003962-A2 | DRUG DELIVERY SYSTEM FOR POORLY WATER SOLUBLE DRUGS | KEMESTRIE INC. (CA) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214677-A1 | Chitosan-Silicon Dioxide Coprecipitate and Use as Excipient in Solid Dosage Forms | SI, SOST, CHIA | MEN1 1072/4885KMT2A 3143/4885EPHX2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.